Lake Street analyst Thomas Flaten maintained a Buy rating on Better Therapeutics, Inc. (BTTX – Research Report) today and set a price target of $1.50. The company’s shares closed yesterday at $0.21.
Flaten covers the Healthcare sector, focusing on stocks such as Better Therapeutics, Inc., Optinose, and Assertio Therapeutics. According to TipRanks, Flaten has an average return of -14.0% and a 24.21% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Better Therapeutics, Inc. with a $5.25 average price target.
See Insiders’ Hot Stocks on TipRanks >>
BTTX market cap is currently $9.95M and has a P/E ratio of -0.18.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Better Therapeutics, Inc. (BTTX) Company Description:
Mountain Crest Acquisition Corp II is a blank check company.
Read More on BTTX:
